METAIRIE, La. — Philadelphia Eagles coach Nick Sirianni urged his players to “focus and refocus" during their first practice in advance of Super Bowl LIX. “It’s not a normal week,” he said.

SAVA isn't done with simufilam in Alzheimer's disease, the company is set to report results from REFOCUS-ALZ in late Q1'25 or early Q2'25. SAVA had $128.6M in cash and cash equivalents at the end ...

Cassava Sciences' simufilam failed to meet co-primary endpoints in the Phase 3 REFOCUS-ALZ trial for mild-to-moderate Alzheimer's disease. Cassava will discontinue Alzheimer's drug development ...